ERBB2 and breast carcinoma: Although this situation has been proven in studies to be associated with the higher prevalence of aggressive subtypes in young breast cancer, many studies have shown that the relatively less aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype is specifically associated with worse survival in young breast cancer patients [1,4,5].